Chiho Kim
Associate Research Scientist @Columbia University Irving Medical Center
Signup · Get unlimited contacts
WORK HISTORY
Associate Research Scientist @Columbia University Irving Medical Center
New York, NY, US
Identified the novel E3 ubiquitin ligase RNF114 through TMT-based quantitative mass spectrometry (MS) in the DNA damage repair system across diverse human cancers • Examined the mechanism/effect of the natural product nimbolide (RNF114 inhibitor) on overcoming PARPi-resistant tumors (e.g, ovarian, breast cancers and glioblastoma) using in vitro systems and in vivo mouse xenograft model systems• Examined the drug combination effect of nimbolide and its immunomodulatory roles • Synthesized and developed more effective nimbolide analogues (via SAR study) • Led the further exploration of nimbolide in targeting tumor cell death, focusing on drug potency and activity• Identified and validated undruggable target proteins/sites of nimbolide via chemoproteomics (e.g, ABPP)• Investigated the antitumor activity of ADP-ribose as the activator of immune cells• Developed and investigated the role of PARP2 PROTAC compound in PARPi-induced hematological toxicity using lymphoblast cells (e.g, K562, MOLT-4 and Jurkat) • Uncovered the MoA of tankyrase PROTAC compounds in the Wnt/β-catenin signaling pathway of cancers• Collaborated with organic chemists and high-throughput screening (HTS) groups
EDUCATION
Yonsei University
Doctor of Philosophy - PhD, Biology/Biological Sciences, General
Sogang University
Bachelor of Science - BS, Life science
ABOUT CHIHO KIM
Highly motivated, experienced and self-driven scientist (10+ yrs) in various human diseases, including oncology, immune-oncology, neurodegenerative diseases, etc• Specialized in 1) the drug discovery with druggable and undruggable target/ligand identification/validation using diverse cellular/phenotypic screening approaches (e.g,(chemo)-proteomics and high-throughput screening); 2) uncovering the mechanism of action of novel targets and/or drug candidates in cell death and drug-resistant system (e.g, in diverse intrinsic/extrinsic signaling pathways, including ubiquitin-proteasome system); 3) development of new drug modality (e.g, targeted therapy, including PROTAC, MG ADC, etc); and 4) development of novel drug mono-/combination-therapy• Established and developed innovative methodologies/assays for diverse human disease models • Demonstrated proficiency in a range of cell/molecular biology in vitro/in vivo (e.g, diverse cell (co-)culture, cloning, cell/gene engineering using CRISPR-Cas9 system, transfection, viral transduction, protein expression/purification, flow cytometry, qRT-PCR, PPI, cellular thermal shift assay (CETSA, for protein-small molecule interaction), confocal/high content imaging (including FRET/BRET), etc), relevant cell-based and biochemical assays (e.g, viability/cytotoxic assays, IP, WB, ELISA, HTS, HiBiT, etc) and large-scale “omics” dataset interpretation and visualization• Enjoy problem-solving and love a collaborative team atmosphere (e.g, a collaboration with Pfizer (La Jolla, CA), organic chemists, etc)• Has a strong scientific track record proven by 20+ publications, diverse awards, 15+ presentations, and the patent
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.